Latest Healthcare News

Australian Foundation Investment Company (ASX:AFI) posted a 3% increase in net profit for FY26, holding dividends steady with a special payout amid portfolio underperformance against the ASX 200.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.

Imricor Medical Systems has officially launched its US commercial operations, securing Rady Children’s Hospital–San Diego as the first customer for its NorthStar iMR mapping system, following key FDA clearances including pediatric approvals.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

ECS Botanics plans to introduce two 2g all-in-one vape products under its OzSun brand in mid-August 2026, expanding its higher-margin B2C portfolio with a capital-efficient supply model.

Austco Healthcare’s subsidiary has locked in a decade-long maintenance contract at Jurong Health Complex, reinforcing its strategy to boost recurring revenue through long-term service agreements.

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.

Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.